Becton Dickinson's Q4 Revenues Rise 7 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson today reported that its revenues rose 7 percent in its fiscal fourth quarter year over year.

For the three months ended Sept. 30, revenues totaled $2.10 billion, compared to $1.97 billion and beat the average analyst estimate of $2.05 billion.

By segment, BD Diagnostics' revenues increased to $680 million from $645 million, while BD Medical rose to $1.12 billion from $1.05 billion. BD Biosciences was up to $208 million from $185 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions. is eyeing an expansion into genomic risk assessments, the Verge reports.